Protocol Ledger

NCT06593600 · Phase II · COMPLETED

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

Interventional Phase II clinical trial protocol NCT06593600 sponsored by Regeneron Pharmaceuticals in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-11-13 Enrollment: 82 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06593600
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)82 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06593600
Protocol FieldVerified Registry Value
NCT IdentifierNCT06593600
Consolidated Lead SponsorRegeneron Pharmaceuticals
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment82 participants (ACTUAL)
Registered Start Date2024-11-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI